Wound Care: Nexodyn® AOS Comes to Fruition in Slovakia
Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based product for acute and chronic wound management, is now available in Slovakia, promoted and commercialized by the pharmaceutical companies Evopharm and Sanomed, pursuant to an exclusive partnership with the Swiss pharma company APR Applied Pharma Research s.a. (“APR”).
After Slovakia, in early 2019 Evopharm will expand the distribution of the product first to Poland, where the registration is currently being completed, and then to Czech Republic.
As confirmed by the results of pre-launch activities, Evopharm is confident that Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, can offer to Slovak Healthcare Professionals (“HCPs”) and caregivers a new treatment option to effectively address the wound healing complexity.
Local KOLs, involved in an Advisory Board, got particularly impressed from the distinctive physico-chemical properties of this product, able to create the ideal microenvironment to sustain the physiological healing process of wounds; clinical evidences have shown Nexodyn® AOS to promote the restart of wound healing, which is considered of great value.
Another benefit of Nexodyn® AOS in interviewed HCPs’ eyes is the local ancillary antimicrobial effect on the wound surface, due to the highly pure and stabilized hypochlorous acid, which can help prevent contamination or contribute to counteract local infections.
“We are very proud about our collaboration with APR and to have the chance to provide Slovak HCPs’ dealing with acute and chronic wounds of such a powerful product. We believe that Nexodyn® AOS, being the first wound cleanser on the Slovak market containing hypochlorous acid, could really make a difference in the treatment of diabetic foot ulcers, lower leg ulcers and pressure ulcers.” commented Martin Hustaty, CEO of Evopharm together with Aneta Manova, CEO of Sanomed.
Sanomed will support the distribution and the promotion of Nexodyn® AOS with a consistent range of activities addressing the HCPs at different levels, from KOLs to hospitals, as well as pharmacists and nurses, like congresses, training courses and e-mailing campaigns, with the purpose of establishing Nexodyn® AOS as the first wound cleanser restarting the physiological healing process of wounds.
”We are very pleased to see Nexodyn® AOS available on Slovak market. This launch comes after previous marketing of the product in Italy, US, Saudi Arabia and UAE, as a result of several partnerships with leading pharmaceutical companies.” said Paolo Galfetti, Chief Executive Officer of APR. “Other markets will follow in the next year confirming Nexodyn® AOS appeal and efficacy among the available wound care solutions”.
About Nexodyn® AcidOxidizing Solution (AOS)
Nexodyn® AcidOxidizing Solution (AOS) is a sprayable Active Cleanser with an ancillary antimicrobial activity developed for acute and chronic wound management.
A wide array of clinical experiences and studies demonstrated Nexodyn® to be a unique Wound healing Restarter by creating the ideal microenvironment to sustain the physiological healing process. Restarting wound healing, favoring an optimized lesion closure and ensuring a favorable safety and tolerability profile, is especially relevant with chronic wounds.
Developed based on APR’s proprietary and patented technology Tehclo®, the product is a newly conceived solution with three main features: highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), acidic pH (2.5 – 3.0) and high Reduction-Oxidation Potential (ORP >1.000 mV).
Nexodyn® AcidOxidizing Solution (AOS) is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, and vascular ulcers), post-surgical wounds, burns and other lesions.
As observed in non-clinical experiments and clinical experiences, Nexodyn® AcidOxidizing Solution (AOS) has synergic physico-chemical properties sustaining the restart of wound healing to the benefit of patients and HCPs who can be confident of the reactivation of the physiological healing process concomitantly to protection and management of uncontrolled microbial growth. Nexodyn® AcidOxidizing Solution (AOS) shows favorable safety and tolerability profile and the clinical experiences performed confirm its high relief sensation and comfort at application as well as wound-associated pain reduction.
For more info, please visit: http://www.apr.ch/apr-pharma-products/medical-prescription/nexodyn-wound-healing/
About APR Applied Pharma Research s.a.
APR is a Swiss independent pharma company focused on development and commercialization of innovative, science-driven products designed to address unmet needs in niche or rare therapeutic areas on a global basis.
APR combines drug development expertise with proprietary drug delivery technologies to deliver to patients suffering from rare diseases with solutions meaningfully improving their life and empowering caregivers with better ways to manage such rare diseases.
APR has a balanced portfolio of revenue generating products marketed in all major markets, combined with a compelling pipeline of innovative products at different stages of development, specifically in the treatment of rare recessive metabolic disorders, rare dermatological and ocular diseases.
APR’s products are commercialized by APR directly through its own sale and marketing teams in selected countries of Europe as well as through a solid global network of commercial partners.
About Evopharm and/or Sanomed
Since 2010 Evopharm brings a high quality, safe and affordable medicines to the market. Our mission is to provide effective solutions for our patients and help them to live a full and happy life. Our commitment to deliver a high quality and professional service is characterized by the status of a rapidly evolving institution. Complex care management in the field of medicines is realized in Central and Eastern Europe and in selected Asian countries. We naturally pay an attention to the ethical, social and environmental dimensions in our every action and decision.
SANOMED is a dinamically-evolving pharmaceutical company operating in Central and Eastern Europe, contributing a large medicine portfólio to the market since 2011. We provide our business partners with a complex package of services from introductory works, registration, launching of the product to its selling and gaining the expected market share. Our effective and safe medicine from many therapeutic fields returns hopes of a full life to people. We strive to improve patient´s health and quality of life and to be a reliable partner to our clients and associates working in healthcare and pharmaceutical industries.
„We´re doing our best to be beneficial to patients and our healthcare partners alike”.
APR Applied Pharma Research s.a.:
Elisabetta Bianchi, Corporate Communication Manager
T +41 91 6957020 or e-mail to: email@example.com
Silvia Matliakova, Product Manager
e-mail to: firstname.lastname@example.org
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Enamine Extends Multi-Year Drug Discovery Collaboration with Lundbeck26.3.2019 12:17:00 EET | Tiedote
Enamine Ltd. a provider of integrated drug discovery services empowered by the world’s largest collections of building blocks and screening compounds, and H. Lundbeck A/S (Lundbeck), the global pharmaceutical company involved in the research of new drugs for the treatment of disorders in the central nervous system, today announced the expansion of their research collaboration. Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs. A large diverse library of 100,000 new screening compounds for hit finding activities on numerous therapeutic targets. Enamine’s make-on-demand REAL compounds (Nature, 2019, Vol. 566, p. 224–229) for efficient access to billions of novel chemical compounds. An increased dedicated team of Enamine FTE chemists to effectively support Lundbeck on all hit related follow-up activities backed by immediate access to over 170
Acuris Risk Intelligence launches Acuris Cybercheck26.3.2019 12:00:00 EET | Tiedote
Acuris Risk Intelligence, a trusted and independent provider of data intelligence for anti-money laundering, anti-corruption and cyber security professionals, today announces the launch of Acuris Cybercheck, a database that allows businesses and individuals to identify whether or not their information has been compromised by criminals. Acuris Cybercheck provides the largest proprietary database of compromised personal ID data. Complied since 2008, the database includes information traded on criminal websites globally such as identity, personal and financial data. It also allows users to search via APIs against specific records or to continuously monitor data. The database is a one-stop shop for monitoring compromised data, allowing users to, among other things, proactively monitor personal data and receive alerts, mitigate identified risks, improve GDPR compliance, provide evidence of potential data breach and assess data compromise in M&A and corporate transactions. The system uses sk
GlobalLogic Appoints Veteran CEO Björn Ivroth as Board Advisor26.3.2019 11:00:00 EET | Tiedote
GlobalLogic Inc., a leader in digital product engineering, today announced that, effective immediately, Björn Ivroth joins the company as an advisor to its Board of Directors. Mr. Ivroth recently served as the CEO of EVRY, a leading Nordic IT services and software provider. In this role, he will work alongside the Board, the CEO, and fellow accomplished leaders contributing to the development and execution of growth strategies driving GlobalLogic’s European business. “We are thrilled to have someone of Björn’s caliber as part of our advisory team,” said Shashank Samant, CEO, GlobalLogic. “His experience as an operating leader, and deep knowledge of the European market are tremendous assets to GlobalLogic, and we are looking forward to leveraging his expertise as we continue to expand our European footprint.” Mr. Ivroth started his career as a Management Consultant at McKinsey & Company. Other early experiences include leadership roles focused on IT Services at Accenture and IBM. His ca
European MSPs Could Lose SMB Clients Over Cybersecurity: Vanson Bourne Report26.3.2019 11:00:00 EET | Tiedote
Cybersecurity demands of small- and medium-sized businesses (SMBs) have become both a major risk and revenue opportunity to managed service providers (MSPs). This is according to research conducted by Vanson Bourne and commissioned by Continuum ®, the proactive platform that integrates intelligent software with expert services for MSPs to scale dynamically and protect their clients. Underserved and Unprepared: The State of SMB Cyber Security in 2019, released today, draws on data collected in 2019 from 850 SMBs across the United States, United Kingdom, France, Germany and Belgium. In addition to the risks for MSPs, the report also highlights the significant revenue opportunity for providers that deliver the cybersecurity services and solutions SMBs need to protect their businesses. Vanson Bourne’s research in the four European countries found that MSPs are at risk of losing their SMB clients over cybersecurity concerns. More than nine in ten (93 percent) SMBs would consider hiring a ne
Evaluate Ltd. Appoints Deborah Kobewka as Chief Executive Officer26.3.2019 11:00:00 EET | Tiedote
Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Deborah Kobewka as Chief Executive Officer, effective immediately. Deborah succeeds Alex Karle, who joined Evaluate in 2012 as Chief Operating Officer before assuming the role of CEO in 2014. Deborah brings to Evaluate over 30 years of expertise in the global pharmaceutical, healthcare and information sectors. With her successful track record of driving commercial expansion, she is well positioned to accelerate the company’s current growth trajectory. Deborah joins Evaluate from the Department for International Trade in the UK government where she served as Managing Director of Healthcare UK, Lifesciences and Bio-economy. Prior to that, she held senior corporate and operational roles at both private and government organisations in the UK, Europe and Asia, including 24 years at IMS Health (now IQVIA). “Evaluate has an impressive history of pioneering solutions
Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 09:00:00 EET | Tiedote
Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme